Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
verteporfin + ranibizumab
- Development stage
- Phase 4
- Lead developer
- Novartis
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravitreal, Intravenous
01
Overview
This combination therapy involves **verteporfin**, a photosensitizer used in photodynamic therapy (PDT), and **ranibizumab**, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody fragment. Verteporfin is activated by light to cause local damage to neovascular endothelium, while ranibizumab inhibits VEGF to prevent new vessel formation. The combination is used to treat neovascular age-related macular degeneration (AMD), aiming to improve visual outcomes and reduce treatment frequency.
- Other names
- Combination therapy using verteporfin and ranibizumab
02
Targets
Beyond the preview
Go deeper on verteporfin + ranibizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on verteporfin + ranibizumab.